Form 4: Director Topper Boosts NAMS Stake

James N. Topper, a Director and 10% owner of NewAmsterdam Pharma Co N.V., acquired 660 ordinary shares indirectly through affiliated entities.

Summary

• James N. Topper, a Director and 10% owner of NewAmsterdam Pharma Co N.V. (NAMS), reported an acquisition of ordinary shares.
• The transaction involved the purchase of 660 ordinary shares on September 15, 2025.
• The shares were acquired at a weighted average price of $23.6953, with prices ranging from $23.46 to $23.75.
• Following this transaction, Mr. Topper indirectly beneficially owns 3,028,524 ordinary shares through Frazier Life Sciences X, L.P. and 3,801,000 ordinary shares through Frazier Lifesciences Sponsor LLC.
• The total indirect beneficial ownership by Mr. Topper, through these entities, amounts to 6,829,524 ordinary shares.

Sentiment

Score: 8

Explanation: The acquisition of shares by a director and 10% owner indicates strong confidence in the company's future prospects and valuation, which is a positive signal for investors.

Positives

• The acquisition of shares by a Director and 10% owner signals strong insider confidence in the company's current valuation and future prospects.
• Insider buying can often be interpreted by the market as a positive indicator of future performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

Insider buying, particularly by a director and significant owner, is generally viewed as a positive signal within the financial industry, suggesting confidence in the company's prospects. This transaction aligns with typical insider activity patterns where key personnel adjust their holdings based on their outlook for the company.

Related Party Transactions

• The shares were acquired indirectly through Frazier Life Sciences X, L.P. and Frazier Lifesciences Sponsor LLC. James N. Topper is one of two managing members of FHMLS X, L.L.C., which is the general partner of FHMLS X, L.P., which in turn is the general partner of Frazier Life Sciences X, L.P. and the sole member of Frazier Lifesciences Sponsor LLC. This structure indicates a related party transaction where the reporting person has an indirect pecuniary interest.

Stakeholder Impact

• Shareholders may perceive this insider purchase as a positive sign of management's belief in the company's value, potentially boosting investor confidence.
• The transaction reinforces the alignment of interests between a significant owner/director and other shareholders.

Key Dates

Recommendation

The purchase of shares by James N. Topper, a Director and 10% owner, signals strong insider confidence in NewAmsterdam Pharma Co N.V.'s valuation and future performance. Such insider buying, especially from a significant stakeholder, often precedes positive company developments and suggests potential upside for the stock, warranting a 'buy' recommendation.

Keywords

NewAmsterdam Pharma, NAMS, Insider Trading, Form 4, Share Purchase, Director, 10% Owner, James N. Topper, Equity Acquisition, Frazier Life Sciences